Yahoo Finance • 7 days ago
PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the... Full story
Yahoo Finance • 8 days ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an unchanged... Full story
Yahoo Finance • 12 days ago
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reductio... Full story
Yahoo Finance • 15 days ago
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story
Yahoo Finance • 18 days ago
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clini... Full story
Yahoo Finance • 25 days ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • last month
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therap... Full story
Yahoo Finance • last month
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an inv... Full story
Yahoo Finance • last month
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of... Full story
Yahoo Finance • last month
[Cardiomyopathy] Hailshadow/iStock via Getty Images * New data from an open-label study of BridgeBio Pharma's (NASDAQ:BBIO [https://seekingalpha.com/symbol/BBIO]) Attruby (acoramidis) showed that the drug led to a significant reduction... Full story
Yahoo Finance • last month
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - Acoramidis also demonstrated a signifi... Full story
Yahoo Finance • last month
PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story
Yahoo Finance • 2 months ago
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral pres... Full story
Yahoo Finance • 2 months ago
Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold a total of 17,353 shares of common stock on August 18th, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction come... Full story
Yahoo Finance • 2 months ago
Alnylam Pharmaceuticals (NASDAQ:ALNY), a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, has been making significant strides in the treatment of rare diseases, particularly transthyretin-mediated am... Full story
Yahoo Finance • 2 months ago
Technical breakout strategies focus on identifying stocks with solid momentum that are consolidating before their next upward move. The method uses two main metrics: the CHARTMILL TECHNICAL RATING, which measures a stock’s overall trend st... Full story
Yahoo Finance • 2 months ago
Check out the companies making headlines in premarket trading. McDonald's — Shares of the fast food giant gained more than 4% after second-quarter results surpassed analyst estimates. McDonald's earned $3.19 per share after adjustments on... Full story
Yahoo Finance • 2 months ago
Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC transaction since 202... Full story
Yahoo Finance • 2 months ago
Check out the companies making headlines in extended trading. Snap — The social media platform plunged 14% after missing revenue expectations for the second quarter. Snap said it recorded $1.34 billion, slightly under the consensus forecas... Full story
Yahoo Finance • 2 months ago
BRIDGEBIO PHARMA INC (NASDAQ:BBIO [https://www.chartmill.com/stock/quote/BBIO]) REPORTS MIXED Q2 2025 RESULTS AS MARKET REACTS NEGATIVELY BridgeBio Pharma Inc released its second-quarter 2025 financial results, delivering a mixed performa... Full story